RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mayne Pharma Group Stock

Mayne Pharma Group Debt 2024

Mayne Pharma Group Debt

-71.25 AUD

Ticker

MYX.AX

ISIN

AU000000MYX0

WKN

A1C821

In 2024, Mayne Pharma Group's total debt was -71.25 AUD, a -132.34% change from the 220.32 AUD total debt recorded in the previous year.

Mayne Pharma Group Aktienanalyse

What does Mayne Pharma Group do?

Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Mayne Pharma Group's Debt Structure

Mayne Pharma Group's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Mayne Pharma Group's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Mayne Pharma Group’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Mayne Pharma Group’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Mayne Pharma Group stock

What is the debt of Mayne Pharma Group this year?

Mayne Pharma Group has a debt level of -71.25 AUD this year.

What was the debt of Mayne Pharma Group compared to the previous year?

The debt of Mayne Pharma Group has increased by -132.34% compared to the previous year dropped.

What are the consequences of high debt for investors in Mayne Pharma Group?

High debt can pose a risk for investors of Mayne Pharma Group, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Mayne Pharma Group?

Low debt means that Mayne Pharma Group has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Mayne Pharma Group affect the company?

An increase in debt of Mayne Pharma Group can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Mayne Pharma Group affect the company?

A reduction in debt of Mayne Pharma Group can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Mayne Pharma Group?

Some factors that can influence the debt of Mayne Pharma Group include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Mayne Pharma Group so important for investors?

The debts of Mayne Pharma Group are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Mayne Pharma Group take to change the debt?

To change the debt, Mayne Pharma Group can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Mayne Pharma Group pay?

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 16.93 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of 0.78 AUD.

What is the dividend yield of Mayne Pharma Group?

The current dividend yield of Mayne Pharma Group is 16.93 %.

When does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mayne Pharma Group?

Mayne Pharma Group paid dividends every year for the past 1 years.

What is the dividend of Mayne Pharma Group?

For the upcoming 12 months, dividends amounting to 0.78 AUD are expected. This corresponds to a dividend yield of 16.93 %.

In which sector is Mayne Pharma Group located?

Mayne Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.

When did Mayne Pharma Group pay the last dividend?

The last dividend was paid out on 1/27/2023.

What was the dividend of Mayne Pharma Group in the year 2023?

In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.

In which currency does Mayne Pharma Group pay out the dividend?

The dividends of Mayne Pharma Group are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mayne Pharma Group

Our stock analysis for Mayne Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.